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Abstract
Aim: VEGF and AFP mRNA determinations in the blood are promising prognostic factors for patients with HCC. This study
explores their potential prognostic synergy in a cohort of HCC patients evaluated for potentially curative therapies.
Methods: One hundred twenty-four patients with a diagnosis of HCC were prospectively enrolled in the study. Inclusion
criteria were: (a) histological diagnosis of HCC and assessment of tumour grade and (b) determination of AFP mRNA status
and VEGF levels in the blood before therapy.
Results: At baseline evaluation, 40% of the study group had AFP mRNA in the blood (AFP mRNA positive), and 35% had
VEGFw23 pg ml
21 (VEGF positive). Surgery was performed in 58 patients (47%), 54 (43%) had tumour ablation, and 12 had
chemoembolisation (10%). Median follow-up and survival of the study group were 19 and 26 months (range, 1 to 60),
respectively. The association of AFP mRNA and VEGF proved to be prognostically more accurate than their single use in
discriminating the risk of death (ROC curve analysis) and survival probability (Cox analysis). In particular, we identified 3
main molecular stages (pv0,0001): both negative (3-year survival=63%), one positive (3-year survival=40%), both positive
(3-year survival=16%). Multivariate analysis identified BCLC staging, surgery, and molecular staging as the most significant
survival variables.
Conclusions: The preoperative determination of AFP mRNA status and VEGF may potentially refine the prognostic
evaluation of HCC patients and improve the selection process for potentially curative therapies.
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Introduction
The biological history of HCC is closely related to the process of
angiogenesis in neoplastic nodules [1]. Angiogenesis plays an
important role in cancer from the initial stage of carcinogenesis to
the end stage of metastatic disease: first, blood vessels provide a
route for supply of nutrients and oxygen to sustain tumour growth;
second, neovessels provide access for tumour cells to enter the
circulation [2].
During this complex process, a consensual de-differentiation of
HCC and endothelial cells is of paramount importance in
determining tumour aggressiveness as defined by the risk of
vascular invasion and intra-extra hepatic metastasis. This physio-
pathological model explains the crucial prognostic role of tumour
grade and mVI as predictors of overall and disease-free survival in
surgical and non-surgical series [3,4].
In current clinical practise, however, there are no accurate
preoperative diagnostic tools available for tumour grade and mVI
[5], such that only tumour size and number are currently used to
stage HCC patients when determining the therapeutic approach
[6]. This explains why, in currently used HCC staging systems,
there is a substantial variation in prognosis among patients within
the same stage [7].
In this context, circulating molecular markers have the potential
to be used as simple and effective tools to refine the prognostic
prediction and treatment of HCC patients. Among the proposed
circulating molecular markers [8], serum VEGF level [9] and the
presence of AFP mRNA in the blood [10,11] show promise for
patient prognosis.
VEGF is the best known angiogenic factor produced by
tumours (it has mitogenic effects on endothelial cells and promotes
vascular permeability), but recent studies [1] have also shown a
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(mitogenic effects on tumour cells, promotion of HCC de-
differentiation, disruption of HCC cell tight junctions).
AFP mRNA is a specific marker of HCC cells in the circulation
and several studies have shown a correlation with HCC-aggressive
tumour features (nodule size, number, vascular invasion, grading)
[10,12]. It may therefore be considered an indirect marker of
tumour growth and de-differentiation, angiogenesis (vascular
permeability and invasion) and micro-metastasis in advanced cases.
The controversial prognostic accuracy of these biomarkers used
alone, however, has not yet justified their introduction into clinical
practise. We hypothesized that the combination of the most significant
angiogenic factor (VEGF) and the most significant circulating HCC
cell marker (AFP mRNA) could be used to improve the overall
accuracy of HCC prognostic prediction and treatment decisions.
On this basis, we started a prospective observational study for
preoperative determination of VEGF serum levels and AFP
mRNA in a cohort of HCC patients referred to our tertiary level
surgically oriented unit in order to evaluate the indication for
prognosis prediction in potentially curative therapies.
Results
Patient characteristics
In the study period, 124 HCC patients were enrolled. Baseline
patient characteristics are described in Table 1. Median age was
62years (13 to 88), and the male/female ratio was 98/26. All
patients had cirrhotic livers, and 59 (48%) had impaired liver
function (Child-Pugh B–C). The most common ætiology was
HCV. CRPH was diagnosed in 89 patients (78%), whereas general
condition was deteriorated (PST§1) in 22 patients (18%).
The median size of the largest nodule was 3,5 cm (1 cm to
18 cm), and 72 patients (58%) had multi-nodular HCC.
Radiologic diagnosis of gross vascular invasion was made in 31
patients (25%).
All enrolled patients had histological evaluation of percutane-
ous/laparoscopic biopsies (60 patients) or surgical specimens (64
transplanted or resected patients). Poorly differentiated tumours
(G3) were detected in 25 patients (20%). Staging procedures
revealed 64 patients (52%) with Tumour, Nodes and Metastasis
(TNM) III–IV tumours and 36 patients (29%) with BCLC C–D
hepatic disease.
AFP mRNA determinations in blood preoperative samples
yielded a positive result in 50 patients (40%). Serum VEGF values
were higher than 23 pg ml
21 (positive) in 44 patients (35%).
Liver resection was performed on 46 patients: 17 patients had an
anatomic resection (37%), the remaining had a wedge resection. 12
patients (10%) had LT. Six (5%) had laparotomic or laparoscopic
radiofrequency thermal ablation. 48 (38%) had percutaneous
ablation procedures (31 radiofrequency thermal ablation, 17
Percutaneous Alcohol Injection). 12 had TACE (10%).
After the initial therapy described in Table 1, 54 patients (44%
of the cohort) had at least one additional therapy during follow-up:
2 patients had a salvage LT, 2 patients had an additional liver
resection; the remaining 40 had a percutaneous ablation or
TACE. During the study period (2001–20007) none of the patients
were treated with systemic therapy.
Correlation among AFP mRNA, VEGF determinations and
clinical-morphological characteristics
Correlations are described in Table 2. AFP mRNA and VEGF
determinations were significantly related to nodule size, gross
vascular invasion, AFPw29 ng ml
21, TNM and BCLC staging
systems, PST§1, tumour grading, and Child-Pugh B–C stages.
Only AFP mRNA positive results were significantly related to
Alkaline Phosphatase (ALP) and c-glutamiltransferase (GGT)
values and to HCV positive ætiology. Only VEGF determinations
were significantly related to PT values and to CRPH.
Univariate survival analysis
The median follow-up of the 124 enrolled HCC patients was
18,6months (range, 1 to 76). During the follow-up, 65 patients
Table 1. Baseline characteristics of the enrolled patients.
Variables Patients (124)
Median age (years) 62 (13–88)
Sex (males) 98 (80%)
Cirrhosis ætiology
HCV 65 (52%)
HBV 24 (20%)
Alcohol 17 (14%)
Other 18 (14%)
CRPH 89 (72%)
Child-Pugh B–C 63 (51%)
Biochemistry
Albumin (g l
21) 36 (21–55)
PT (%) 70 (31–109)
Bilirubin (mmol l l
21) 21 (6–341)
Creatinine (mmol l l
21) 84 (50–184)
AST (U/l) 76 (17–492)
ALT (U/l) 59 (10–469)
PST$1 22 (18%)
Tumour characteristics
Nodule size (cm) 3,5 (0,8–18)
Multinodular 72 (58%)
Gross Vascular Invasion 31 (25%)
Tumour grading
Well differentiated 47 (38%)
Moderately differentiated 52 (42%)
Poorly differentiated 25 (20%)
UNOS- TNM
I–II 60 (48%)
III 26 (21%)
IV 38 (31%)
BCLC
A 58 (47%)
B 30 (24%)
C–D 36 (29%)
AFP mRNA positive 50 (40%)
VEGF.23 pg ml
21 (positive) 44 (35%)
Therapy
Resection 46 (37%)
LPT/VLS ablation 6 (5%)
PEI- RF 48 (38%)
TACE 12 (10%)
LT 12 (10%)
doi:10.1371/journal.pone.0023093.t001
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complications, and 9 from non-hepatic-related deaths. Median
survival of the study group was 26,4months (range, 1 to 76) and 1,
3, and 5 year survival rates were 71, 46%, and 41%, respectively.
Upon univariate survival analysis (Cox model), the following
variables (Table 3) significantly impacted survival in the study
group: nodule size w3,5 cm, multi-nodular HCC, gross vascular
invasion, grading, AFP mRNA positivity, VEGFw23 pg ml
21,
Child-Pugh B–C, bi-lobar tumour, surgery, PST§1, TNM, and
BCLC. The integrated AFP mRNA/VEGF variable was consid-
ered in two ways. AFP mRNA/VEGF was classified in 3 stages as
both negative ({{), one positive (z{ or {z), both positive
(zz). AFP mRNA/VEGF was also classified in 4 stages as both
negative ({{), AFP mRNA negative ({z), VEGF negative
(z{), both positive (zz).
The Cox model and ROC curve analysis showed that the best
interpretation of survival distribution was given by an association
of AFP mRNA and VEGF in 3 stages (Figures 1–2).
Multivariate survival analysis
Upon multivariate analysis (Table 4) of the overall study group,
BCLC staging, surgery, gross vascular invasion and the AFP
mRNA/VEGF integrated variable maintained a significant
impact on survival.
Molecular staging of homogeneous subgroups of HCC
patients
The AFP mRNA/VEGF integrated variable was also tested in
the following homogeneous subgroups of HCC patients: BCLC A
patients, BCLC B patients and patients treated by resection or
ablation procedures with a curative intent (BCLC A–B patients).
The proposed molecular staging showed significant discrimina-
tory ability (log-rank test applied to Kaplan-Meier analysis) in
BCLC A and B patients (Figure 3, A–B) but not in BCLC C–D
patients (p~0,29). The AFP mRNA/VEGF integrated variable
also showed significant prognostic value in patients undergoing
resection (Figure 4A) and ablation (Figure 4B).
Discussion
This prospective observational study was specifically designed to
evaluate the prognostic role of the preoperative determination of
VEGF serum levels and AFP mRNA in a cohort of HCC patients
in order to evaluate their indication for potentially curative
therapies.
Table 2. Relationship between AFP mRNA/VEGF
determinations and clinical-morphological characteristics of
enrolled HCC patients.
AFP mRNA VEGF
LRX2 (P) LRX2 (P)
Age.62 years 2–14 (0,1430) 5,07 (0,0243)
Sex Male 1,28 (0,2578) 0,13 (0,7211)
Nodule size.3,5 cm 2,60 (0,1069) 7,62 (0,0058)
Multinodular 0,53 (0,4654) 0,03 (0,8636)
Gross vascular invasion 12,91 (0,0003) 15,21 (,0,0001)
VEGF.23 pg ml
21 18,55 (,0,0001) —
AFP mRNA positive — 18,55 (,0,0001)
AFP.29 ng l
21 6,97 (0,0083) 7,27 (0,0070)
CRPH 0,13 (0,7182) 5,41 (0,0200)
Bilobar 2,94 (0,0865) 1,29 (0,2565)
Surgery 0,19 (0,6619) 0,07 (0,7898)
Albumin,36 g l
21 0,31 (0,5783) 0,09 (0,7635)
PT,70% 5,23 (0,0215) 2,40 (0,1209)
Bilirubin.21 mmol l
21 4,20 (0,0404) 2,99 (0,0839)
Creatinine.84 mmol l
21 0,16 (0,6869) 0,68 (0,4097)
AST.76 U/l 0,65 (0,4201) 0,04 (0,8356)
ALT.59 U/l 1,11 (0,2917)) 1,72 (0,1891
ALP.123 U/l 1,70 (0,1927) 0,06 (0,8011)
GGT.68 U/l 3,29 (0,0695) 0,09 (0,7635)
Child- Pugh B–C 0,02 (0,8826) 0,02 (0,8940)
TNM 18,34 (0,0001) 22,09 (,0,0001)
BCLC 13,35 (0,0013) 21,23 (,0,0001)
PST.1 8,63 (0,0033) 6,51 (0,0107)
Grading 58,35 (,0,0001) 13,04 (0,0015)
HCV+ 4,20 (0,0458) 3,04 (0,0812)
LRX2, likelihood ratio X2 test.
doi:10.1371/journal.pone.0023093.t002
Table 3. Univariate survival analysis: significant survival
predictors in the study group.
Variable Hazard Ratio
(95% CI) p Value
Nodule size.3,5 cm 1,28 (1,00–1,65) 0,0461
Multinodular 1,31 (1,01–1,70) 0,0373
Macroscopic vascular invasion 4,01 (2,42–6,57) ,0,0001
Grading
Moderately versus well differentiated 2,88 (1,53–5,73) ,0,0001
Poorly versus moderately differentiated 2,40 (1,36–4,16)
AFP mRNA positive 3,22 (1,97–5,33) ,0,0001
VEGF.23 pg ml
21 2,37 (1,45–3,87) 0,0007
AFP mRNA/VEGF (3 stages)
2 + or + 2 versus 22 2,21 (1,20–4,08) ,0,0001
++versus 2 + or + 2 2,31 (1,28–4,20)
AFP mRNA/VEGF (4 stages)
2+ versus 22 1,78 (0,74–3,90) ,0,0001
+2 versus 2+ 1,56 (0,69–3,85)
++ versus +2 1,79 (0,94–3,50)
Bilobar 1,74 (1,01–2,92) 0,0479
Child-Pugh B–C 1,40 (1,09–1,80) 0,0076
Surgery 1,64 (1,28–2,13) 0,0001
PST.1 4,12 (2,37–6,93) ,0,0001
TNM
III versus I–II 1,91 (0,94–3,78) ,0,0001
IV versus III 2,55 (1,38–4,97)
BCLC
B versus A 2,04 (1,00–4,15) ,0,0001
C–D versus B 3,52 (1,94–6,71)
AFP mRNA/VEGF (3 stages): stage 1=22 , stage 2=2 + or + 2, stage 3=++ .
AFP mRNA/VEGF (4 stages): stage 1=22 , stage 2=2 +, stage 3=+ 2, stage
4=++ .
doi:10.1371/journal.pone.0023093.t003
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by considering the potential utility of these still experimental
molecular markers in daily clinical practise.
Prognostic factors may help the treatment strategy for HCC
patients in different ways:
1. in deciding the best therapy according to patient characteris-
tics;
2. in estimating individual survival perspectives;
3. in designing clinical trials to test new therapies;
4. in programming post-treatment follow-up and adjuvant
therapy;
Prognostic prediction and therapeutic decisions for HCC
patients in most centres are currently based on macroscopic
tumour characteristics detected by imaging studies (nodule size
and number). In the past decade, the empirical rule of a single
nodule smaller than 5 cm in diameter or multiple nodules (2 or 3)
smaller than 3 cm has been used to define early HCC, with
excellent outcomes achieved after LT [6,13].
These macro-morphological tumour characteristics have been
incorporated in the BCLC classification [14] to discriminate
between early and intermediate/advanced stages. Moreover,
according to this staging system, advanced or terminal stages
may also be identified by severe liver impairment (Child-Pugh C)
or compromised performance independently from tumour stage,
because these characteristics may either limit the individual
therapeutic success or indirectly identify more aggressive tumours.
BCLC staging is now considered the best available prognostic
system for HCC patients [6,7], and our centre has made an
important contribution to the validation of this staging system
[15,16], particularly in populations mainly characterized by
radically treated HCC patients.
Therefore, we agree that BCLC clinical variables (radiological
tumour size, number and vascular invasion; liver function
parameters; performance status) are crucial prognostic factors for
patients with HCC. In addition, in this prospective study, these
variables demonstrated significant discrimination of survival ability
(Table 3) on univariate analysis.
However, there is a substantial variation in prognosis among
patients within the same BCLC stage [7]. This fundamental
concept has been confirmed in the present study, which showed
that molecular staging had significant predictive ability on
multivariate analysis, together with surgery and BCLC staging.
The first result of this study, therefore, is that our proposed
molecular staging may potentially refine the prognostic evaluation
of patients with HCC. Circulating prognostic molecular markers
(AFP mRNA and VEGF) showed significant ability in discrimi-
nating survival within BCLC stages, especially when used as an
integrated variable (Figure 3).
The prognostic heterogeneity makes BCLC staging alone
relatively inaccurate for determining the best treatment strategy
and estimating individual prognosis. As shown in recent studies
[17,18], there is a substantial therapeutic hierarchy within each
BCLC stage that is prognostically characterized by surgery as the
first therapeutic option, percutaneous ablation as the second,
TACE as the third, and, finally, systemic therapies as the fourth.
This evidence was also confirmed in the present analysis by
multivariate analysis, which showed the prognostic independence
of surgical therapy with respect to BCLC staging (Table 4).
Thus, in therapeutic decisions, negative prognostic factors do
not necessarily coincide with absolute exclusion criteria for a
specific therapy. For example, multi-nodularity, vascular invasion
and portal hypertension [19,20] in Child-Pugh A patients are
negative prognostic factor for patients undergoing liver resection
but the therapeutic alternatives in these subgroups of patients are
often very poor. In this view, the proposed BCLC treatment
algorithm [7] may not be used to formulate strict therapeutic
guidelines [6].
The small sample size in this study does not allow us to reach
definitive conclusions about the potential role of these molecular
markers in treatment decision. On a purely speculative basis, the
results of this study suggest the potential utility of these biomarkers
in excluding potentially curative therapies for BCLC B patients
with a poor prognosis (those with a simultaneously positive blood
value for AFP mRNA and VEGF, Figure 3B).
As a third point, these prognostic factors should help design
RCT stratifying the overall HCC populations in prognostically
homogeneous subgroups. In this context, the BCLC system has the
relevant merit of favouring the development of RCT, especially in
the complex field of HCC treatment assessment [21,22]. From
these perspectives, molecular markers probably do not add much
to this particular clinical and scientific field.
However, post-treatment follow-up and adjuvant therapy
concerns remain a crucial and non-standardized problem. The
Figure 1. ROC curve analysis. Relationship between patient mortality and AFP mRNA used alone (A), VEGF used alone (B), and the integrated use
of the 2 markers (C).
doi:10.1371/journal.pone.0023093.g001
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within 5years from treatment, despite undergoing potentially
curative therapies such as resection or ablation [23]. Moreover, to
extend the indication of potentially curative therapies to BCLC B
patients as well, it would be important to reduce the risk of post-
treatment recurrence or to make an early diagnosis.
In this view, molecular markers capable of discriminating the
prognosis of patients within BCLC stages could be important for
post-treatment follow-up and preventive therapy.
The second fundamental result of this study is that blood AFP
mRNA and VEGF showed a relevant prognostic ability in BCLC
A–B patients (Figure 3, A & B), particularly in selected subgroups
undergoing resection or ablation (Figure 4, A & B). Although this
study was not specifically designed to study post-treatment
recurrence, our results suggest that patients with one or two pre-
operatively positive molecular markers should be strictly moni-
tored and could eventually undergo adjuvant therapies in order to
improve their post-treatment prognosis.
Their strong correlation with tumour grade and vascular
invasion (Table 2) and their prognostic power (Table 3, Table 4)
suggest that blood AFP mRNA and VEGF are direct markers of
biological tumour aggressiveness.
In light of the recent introduction of molecular targeted
therapies [24] acting on pathways of tumour biological progres-
sion, it is possible that our proposed molecular staging might help
to select HCC patients with higher potential for good response to
these new therapies. In particular, this may be true for Sorafenib
[22], which mainly acts by inhibiting VEGF cellular signalling
implicated in HCC pathogenesis and progression.
Previous experiences exploring the prognostic role of preoper-
ative AFP mRNA and VEGF have yielded controversial results
[8,9,12]. It is likely that these biologic HCC parameters alone do
Figure 2. Prognostic classification of the study group according to AFP mRNA/VEGF. Molecular staging of HCC patients: integrated
variable (3 stages). Log rank test: pv0,01.
doi:10.1371/journal.pone.0023093.g002
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tions undergoing potentially curative therapies. The present study
suggests that in the context of a larger population basis, AFP
mRNA and VEGF may be useful for both prognostic assessment
and treatment decisions, especially when used as an integrated
variable. The introduction of appropriate molecular methods for
quantifying AFP mRNA in the blood and larger studies to identify
the exact prognostic range of VEGF will further improve the
prognostic power of these promising biomarkers.
In conclusion, this study has shown that preoperative determi-
nation of blood AFP mRNA and VEGF may potentially refine the
prognostic evaluation of HCC patients. On a purely preliminary
basis, these two parameters may help in the treatment decision
process for HCC patients eligible for potentially curative therapies,
consequently improving the currently used restrictive selection
criteria.
Methods
Ethics Statement
In the period the study was realized (2001–2007) the Ethics
Committee of our institution at the University Hospital of Padua
did not specifically require an explicit approval for anonymized
prospective observational studies. Patients were informed about
the research, but no informed consent was requested since all data
was anonymized.
Study design
This prospective observational study started in January 2001.
Inclusion criteria were: (a) histological diagnosis of HCC and
assessment of tumour grade (percutaneous biopsy or histology of
surgical specimens); (b) baseline determination of AFP mRNA
status and VEGF levels in the blood; and (c) a general consent for
the use of a blood sample for research purposes. Exclusion criteria
were: (a) fibrolamellar HCC; (b) concomitant extra-hepatic
tumour; (c) HIV positivity; and (d) previous recent HCC treatment
(v6months).
Table 4. Evaluation of the independent contribution of each
variable to Cox Proportional Hazard Model. Multivariate
Survival Analysis using AFP mRNA and VEGF as an integrated
variable.
Variable Hazard Ratio
(95% CI) p Value
Nodule size.3,5 cm 1,24 (0,87–1,78) 0,2389
Multinodular 1,28 (0,92–1,82) 0,1481
Macroscopic vascular invasion 0,35 (0,12–1,01) 0,0517
Grading
Moderately versus well differentiated 1,76 (0,84–3,81) 0,1049
Poorly versus moderately differentiated 1,54 (0,74–3,25)
AFP mRNA/VEGF (3 stages)
2 + or +2 versus 22 2,36 (1,14–4,99) 0,0305
++versus 2 + or + 2 1,12 (0,52–2,41)
Bilobar 0,72 (0,36–1,40) 0,3360
Child- Pugh B–C 1,26 (0,93–1,74) 0,1379
Surgery 1,66 (1,22–2,30) 0,0011
PST.1 1,33 (0,64–2,72) 0,4351
TNM
III versus I–II 1,58 (0,60–4,07) 0,6306
IV versus III 0,89 (0,38–2,15)
BCLC
B versus A 0,74 (0,29–1,91) 0,0055
C–D versus B 6,30 (2,08–18,53)
AFP mRNA/VEGF (3 stages): stage 1=22 , stage 2=2 + or + 2, stage 3=++ .
AFP mRNA/VEGF (4 stages): stage 1=22 , stage 2=2 +, stage 3=+ 2, stage
4=++ .
doi:10.1371/journal.pone.0023093.t004
Figure 3. Molecular staging of HCC patients. Comparison between BCLC A (A) and BCLC B (B) stages. Log rank test: p~0,04 (A), and p~0,01 (B).
doi:10.1371/journal.pone.0023093.g003
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recorded the following variables: age, sex, and cirrhosis ætiology;
PST, presence of CRPH defined as the presence of gastro-
œsophageal varices, splenomegaly with a platelet count of less than
100000 cells/ml, ascites; main serological parameters [total
bilirubin, AST, ALT, PT, albumin, ALP, GGT, creatinin];
Child-Pugh class; and tumour characteristics [number and size
of lesions, gross vascular invasion, metastasis, AFP levels, UNOS-
TNM (TNM) [13], and BCLC staging [14]. Microscopic vascular
invasion could only be determined in a minority of cases due to
lack of a surgical specimen, thus this variable could not be studied.
Blood samples for AFP mRNA and VEGF determinations were
taken 2 h to 48 h before therapy. The minimum follow-up for all
patients included a clinical visit, hepatic US, and blood analysis
with AFP levels every 3 months in the first year and every 6
months in the second and third years.
AFP mRNA determination
An EDTA-K3-supplemented blood sample (7 ml) was obtained
from all subjects and immediately stored at 4uC for no more than
3 h until processing. Total RNA was extracted and converted to
cDNA. A nested polymerase chain reaction protocol was
performed as previously reported [10]. Positive results were
observed as a 282 bp band in an agarose gel stained with
ethidium bromide. As positive control, cDNA obtained from the
hepatocellular carcinoma cell line HepG2 was used in each run.
Negative controls for each step were also included. The sensitivity
of AFP mRNA determination was 10 cells in 7 ml of blood and
measured by diluting HepG2 cells in blood samples obtained from
negative subjects.
Serum determinations
A serum sample was also obtained from each subject and stored
at 220uC until use in AFP protein and VEGF immunoassays
(Bayer, Milan, Italy, and BioSource International, Nivelles,
Belgium, respectively). The sensitivity of the assay for VEGF was
23 pg ml
21, which was the minimum VEGF concentration with a
coefficient of variation of less than 20%. The intra-assay precision
for VEGF was less than 5% in the concentration range
87 pg ml
21 to 938 pg ml
21. The intra-assay precision for AFP
protein was less than 5% in the range 20 ng ml
21 to 732 ng ml
21.
Plasma determination
All patients were also tested for albumin, bilirubin, creatinin,
AST, ALT, ALP, GGT and PT using standard methods.
Treatment algorithm
All enrolled patients were referred to our tertiary hepatobiliary
surgery-liver transplantation unit to evaluate the feasibility of
potentially curative therapies. Patients in BCLC A–B stages were
considered for surgery or ablation procedures eventually associ-
ated with TACE: as previously reported [25], the rate of
anticancer therapeutic aggressiveness in these patients was
determined at our institution mainly by liver function parameters
such as Child-Pugh class, CRPH and, in the last 4years, the
MELD score, whereas nodule size and number were not absolute
criteria for assigning potentially curative treatment (Figure 5). LT
was considered a salvage treatment for all patients having HCC
persistence/progression or recurrence or having severe liver
function impairment (BCLC D). Absolute exclusion criteria for
LT were [26]: general contraindications (age, extra-hepatic
disease, compliance) or aggressive tumour features (poorly
differentiated grade, gross vascular invasion, metastasis).
Patients with advanced tumours (gross vascular invasion,
metastasis) but good liver function (BCLC C) were eventually
considered for surgery or ablation only from a palliative
perspective.
Aims of the study
1. To investigate the correlation between AFP mRNA and
VEGF determinations and clinical-morphological characteristics
of enrolled HCC patients.
2. To evaluate the prognostic role of AFP mRNA and VEGF
determinations used alone or together as an integrated variable.
Figure 4. Molecular staging of surgically treated BCLC A–B HCC patients. Patients treated by resection (A) or ablation procedures (B).
doi:10.1371/journal.pone.0023093.g004
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The patients’ baseline characteristics are expressed as medians
(range) for continuous data and as frequencies (percentage) for
categorical data. There were only 9 (7%) Child-Pugh C patients;
thus, we considered only 2 stages, Child-Pugh A and B–C. Child-
Pugh C patients were considered BCLC D only when they were
without LT therapeutic perspectives. Because the TNM I stage
included only 9 patients (7%) and the BCLC D stage only 4
patients (3%), the following variables were stratified in three main
stages: BCLC A, B, C–D and TNM I–II, III, IV, respectively.
Because only 44 patients (35%) had a serum VEGF value higher
than 23 pg ml
21 (sensitivity of the assay), this variable was
considered a categorical variable identifying the 2 subgroups of
patients with VEGF valuesw23 pg ml
21 (positive) or
ƒ23 pg ml
21 (negative). Comparisons between groups were
analyzed by logistic regression, the x2 test or Fisher’s exact test,
as appropriate. Follow-up and survival times are expressed as
medians (range). Survival was calculated from the day of AFP
mRNA/VEGF determinations until death or latest follow-up. The
study period was between January 2001 (first enrolment) and
September 2007 (last follow-up).
Cox’s univariate proportional hazards models were used to
identify potential survival predictors in the study group. Cox
regression and ROC curve analysis were used to evaluate the
interaction between AFP mRNA and VEGF determinations and
to determine the prognostic utility of a potential integrated
variable, taking into account both molecular markers.
A Cox’s multivariate model was then created, including only
variables with pv0,05 at univariate analysis.
Probability curves for survival were calculated using the
Kaplan-Meier method, and the log-rank test was applied to the
Kaplan-Meier curves to identify potential predictors of survival.
In order to reduce the confounding effect of treatment and
staging on survival response variables, the prognostic impact of the
molecular markers was also tested in subgroups of BCLC A,
BCLC B, and BCLC A–B patients undergoing resection or
ablation.
Statistical significance was set at pv0,05, and calculations were
performed with the JMP package (1989 to 2003 SAS Institute
Inc.).
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